Free Trial

Beta Bionics (NASDAQ:BBNX) Earns Buy Rating from Analysts at Lake Street Capital

Beta Bionics logo with Medical background

Equities researchers at Lake Street Capital began coverage on shares of Beta Bionics (NASDAQ:BBNX - Get Free Report) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a "buy" rating and a $30.00 price target on the stock. Lake Street Capital's price objective would indicate a potential upside of 57.15% from the stock's previous close.

Several other research firms also recently weighed in on BBNX. Stifel Nicolaus started coverage on Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating and a $25.00 price target on the stock. Wolfe Research began coverage on Beta Bionics in a report on Friday, May 30th. They set an "outperform" rating and a $20.00 price target on the stock. The Goldman Sachs Group began coverage on Beta Bionics in a report on Friday, May 30th. They set a "neutral" rating and a $16.00 price target on the stock. LADENBURG THALM/SH SH began coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price objective for the company. Finally, Leerink Partnrs upgraded Beta Bionics to a "strong-buy" rating in a research note on Monday, February 24th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $23.13.

Get Our Latest Analysis on BBNX

Beta Bionics Stock Performance

NASDAQ:BBNX traded down $0.40 during trading hours on Thursday, hitting $19.09. 454,762 shares of the company's stock traded hands, compared to its average volume of 499,635. Beta Bionics has a 52 week low of $8.89 and a 52 week high of $24.50. The company has a fifty day moving average of $13.92.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Insiders Place Their Bets

In related news, CFO Stephen Feider sold 1,497 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $26,781.33. Following the completion of the sale, the chief financial officer now owns 45,503 shares of the company's stock, valued at approximately $814,048.67. This represents a 3.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 4,519 shares of company stock worth $80,845.

Institutional Trading of Beta Bionics

Several hedge funds have recently made changes to their positions in BBNX. Strs Ohio acquired a new position in shares of Beta Bionics in the 1st quarter worth approximately $29,000. Corebridge Financial Inc. purchased a new position in shares of Beta Bionics in the 1st quarter valued at $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Beta Bionics in the 1st quarter valued at $95,000. MetLife Investment Management LLC purchased a new position in Beta Bionics during the 1st quarter worth $102,000. Finally, Deutsche Bank AG acquired a new stake in shares of Beta Bionics in the 1st quarter worth $148,000.

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Recommended Stories

Analyst Recommendations for Beta Bionics (NASDAQ:BBNX)

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines